Also known as: NSF
Federal and international funders have announced life sciences and biotech funding opportunities: NIH awards up to $30 million, NSF fellowships, and roundups exceeding $900 million. Scholarships and grants are open worldwide, with AI and local eligibility as key criteria.
Flow chemistry, laboratory mixer, and industrial extruder markets are projected to grow significantly through 2035, driven by pharmaceutical continuous manufacturing, high R&D funding, and sustainability trends. Flow chemistry is expected to reach $12 billion, while laboratory mixers could hit $29.6 billion. Key players include Merck KGaA, BASF, and Lonza.
A federal judge blocked grant terminations based on changed priorities; OMB proposes political control over awards. Ph.D. enrollment declines as funding uncertainty persists, and science leaders urge advocacy.
UC Davis received a $5 million Gates Foundation grant to expand self-cloning crops to other staple foods. Congress approved continued NIH and NSF funding, maintaining similar levels to the previous year. Faculty and students emphasized federal funding's role in supporting basic research and training scientists.
The FDA has accepted Ascelia Pharma's NDA for Orviglance, a manganese-based oral MRI contrast agent for liver imaging in patients with severe kidney impairment, and set a PDUFA action date of July 3, 2026.
Congress rejected the administration’s deepest proposed science cuts, increasing NIH funding by about $415 million to $48.7 billion. NASA and NSF also saw far smaller reductions than proposed.
Trump proposed significant cuts to major US science agencies for 2027, including a 13% reduction for the NIH and a nearly 55% cut for the NSF. The administration also let lapse its Supreme Court deadline in a separate fight to cap NIH research overhead payments at 15%.
Thousands of research positions have been terminated or frozen at federal agencies following deep cuts to U.S. science funding by the Trump administration, affecting work from aging studies to global food security.
National Institutes of Health Director Jay Bhattacharya will serve as acting director of the Centers for Disease Control and Prevention following Jim O'Neill's departure. Bhattacharya will oversee both agencies simultaneously as the CDC faces significant instability.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT06916377 |
The Economics of Domestic Violence: Evidence From Bangladesh |
ACTIVE_NOT_RECRUITING | NA |
| NCT04094571 |
Muscle Delay Characterization |
COMPLETED | NA |
| NCT03096262 |
Transforming Robot-mediated Telerehabilitation: Citizen Science for Rehabilitation |
COMPLETED | NA |
